Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Boshuizen J, et al. Among authors: ligtenberg ma. Nat Commun. 2020 Aug 7;11(1):3946. doi: 10.1038/s41467-020-17739-8. Nat Commun. 2020. PMID: 32770055 Free PMC article.
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI. Boshuizen J, et al. Among authors: ligtenberg ma. Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15. Nat Med. 2018. PMID: 29334371
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS. Vredevoogd DW, et al. Among authors: ligtenberg ma. Cell. 2019 Jul 25;178(3):585-599.e15. doi: 10.1016/j.cell.2019.06.014. Epub 2019 Jul 11. Cell. 2019. PMID: 31303383 Free article.
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS. Vredevoogd DW, et al. Among authors: ligtenberg ma. Cell. 2020 Jan 23;180(2):404-405. doi: 10.1016/j.cell.2020.01.005. Cell. 2020. PMID: 31978349 Free article. No abstract available.
Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.
Theelen WSME, Krijgsman O, Monkhorst K, Kuilman T, Peters DDGC, Cornelissen S, Ligtenberg MA, Willems SM, Blaauwgeers JLG, van Noesel CJM, Peeper DS, van den Heuvel MM, Schulze K. Theelen WSME, et al. Among authors: ligtenberg ma. J Transl Med. 2020 Jul 3;18(1):271. doi: 10.1186/s12967-020-02436-3. J Transl Med. 2020. PMID: 32620126 Free PMC article.
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Boshuizen J, Pencheva N, Krijgsman O, Altimari DD, Castro PG, de Bruijn B, Ligtenberg MA, Gresnigt-Van den Heuvel E, Vredevoogd DW, Song JY, Visser N, Apriamashvili G, Janmaat ML, Plantinga TS, Franken P, Houtkamp M, Lingnau A, Jure-Kunkel M, Peeper DS. Boshuizen J, et al. Among authors: ligtenberg ma. Cancer Res. 2021 Apr 1;81(7):1775-1787. doi: 10.1158/0008-5472.CAN-20-0434. Epub 2021 Feb 2. Cancer Res. 2021. PMID: 33531370
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
Krijgsman O, Kemper K, Boshuizen J, Vredevoogd DW, Rozeman EA, Ibanez Molero S, de Bruijn B, Cornelissen-Steijger P, Shahrabi A, Del Castillo Velasco-Herrera M, Song JY, Ligtenberg MA, Kluin RJC, Kuilman T, Ross-Macdonald P, Haanen JBAG, Adams DJ, Blank CU, Peeper DS. Krijgsman O, et al. Among authors: ligtenberg ma. Clin Cancer Res. 2021 Oct 1;27(19):5389-5400. doi: 10.1158/1078-0432.CCR-20-4218. Clin Cancer Res. 2021. PMID: 34230026
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.
Apriamashvili G, Vredevoogd DW, Krijgsman O, Bleijerveld OB, Ligtenberg MA, de Bruijn B, Boshuizen J, Traets JJH, D'Empaire Altimari D, van Vliet A, Lin CP, Visser NL, Londino JD, Sanchez-Hodge R, Oswalt LE, Altinok S, Schisler JC, Altelaar M, Peeper DS. Apriamashvili G, et al. Among authors: ligtenberg ma. Nat Commun. 2022 Apr 8;13(1):1923. doi: 10.1038/s41467-022-29442-x. Nat Commun. 2022. PMID: 35395848 Free PMC article.
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.
Zhang Z, Kong X, Ligtenberg MA, van Hal-van Veen SE, Visser NL, de Bruijn B, Stecker K, van der Helm PW, Kuilman T, Hoefsmit EP, Vredevoogd DW, Apriamashvili G, Baars B, Voest EE, Klarenbeek S, Altelaar M, Peeper DS. Zhang Z, et al. Among authors: ligtenberg ma. Cell Rep Med. 2022 Jun 21;3(6):100655. doi: 10.1016/j.xcrm.2022.100655. Epub 2022 Jun 9. Cell Rep Med. 2022. PMID: 35688159 Free PMC article.
26 results